Patient centred approach to bladder cancer treatment development
Research type
Research Study
Full title
Taking a combined technology driven and patient-centred approach to the development of next-generation bladder cancer treatments
IRAS ID
312796
Contact name
Katrina Taylor
Contact email
Sponsor organisation
University of Kent
Clinicaltrials.gov Identifier
DOI 10.17605/OSF.IO/WVT79, Study registration Open Science Framework
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Background
This study is taking a combined laboratory and patient-centred approach to the development of next-generation bladder cancer treatments. Bladder cancer kills 200,000 individuals worldwide/year and 10 year survival is less than 50%. Over 570,000 people are diagnosed globally/year and bladder cancer has the highest lifetime treatment costs/patient of all cancers. The current treatment strategy results in a high rate of tumour recurrence, and the need for further treatment.
Preliminary focus groups with bladder cancer patients showed a low level of knowledge about how treatments were developed and worked, yet all expressed a desire to have and understand this information.
This PhD will interweave patient-centred feedback and insights around the challenges of treatments into drug development in a novel way combining patient feedback with health professionals’ insights to develop an educational tool kit to communicate the drug development pathway and treatment action to patients and the public.
Research questions
What are the best ways to increase patients’ understandings of bladder cancer treatments, and how they are developed? What benefit does this have to patients and the public?
How can patient feedback and involvement effectively feed into drug development for new treatments?Eligibility
Patients at EKUHFT who have had a bladder cancer diagnosis or are undergoing treatment, and the health care professionals who support them.
Duration
3 years.
Involvement
A mixed methods approach:
Questionnaires with a wide selection of patients to ascertain their understanding of drug development and treatment action and their interest in learning more;
Qualitative and creative methods in patient groups (potentially within existing support groups) to explore lived experiences of bladder cancer treatment, desires to be involved with and feed into drug development, and ways to effectively engage and communicate. A quantitative evaluation questionnaire will also be used once per year to monitor learning, progress and engagement with patient group participants.REC name
London - South East Research Ethics Committee
REC reference
22/PR/1380
Date of REC Opinion
1 Nov 2022
REC opinion
Further Information Favourable Opinion